Clinical trials: Non-small Cell Lung Cancer Patients
Non-Small Cell Lung Cancer, Carcinoma
Molecular Profiling in Lung Cancer Patients
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in…
- Trial name
- NCT00191308
- Testing
- pemetrexed, cisplatin, Radical Non-Small Cell Lung Cancer (NSCLC) surgery
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Non-Small Cell
Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery
Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.
- Trial name
- NCT00290355
- Testing
- GSK 249553 vaccine
- Where
- 62 sites in Belgium, Estonia and 12 more
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs.
- Trial name
- PANORAMRETRO (NCT03721289)
- Where
- 10 sites in Argentina, Chile and 2 more
- Volunteers
- 463 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Non-Small Cell Lung Cancer
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous…
- Trial name
- NCT02409355
- Testing
- Atezolizumab, Carboplatin, Cisplatin
- Where
- 82 sites in United States, Czechia and 12 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Glioblastoma
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid…
- Conditions
- Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04982926
- Testing
- TAS2940
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Taiho Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The objectives of this study are to assess the safety, tolerability, pharmacokinetics and efficacy of VAL401 in the treatment of patients with locally advanced or metastatic non-small cell lung adenocarcinoma.
- Trial name
- NCT02875340
- Testing
- VAL401
- Volunteers
- 8 people
- Sponsor
- ValiSeek Limited
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the…
- Trial name
- Brilliant (NCT05721950)
- Testing
- Brigatinib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Takeda
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
- Trial name
- NCT04449874
- Testing
- GDC-6036, Atezolizumab, Cetuximab
- Where
- 63 sites in United States, Australia and 15 more
- Volunteers
- 498 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
- Trial name
- NCT02635061
- Testing
- ACY-241, Nivolumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Celgene
Squamous Cell Non-small Cell Lung Cancer
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after…
- Trial name
- NCT01721759
- Testing
- Nivolumab
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.
Oncology, Solid Tumor
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
- Conditions
- Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03637803
- Testing
- MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- Where
- 5 sites in United States
- Volunteers
- 63 people
- Sponsor
- 4D pharma plc
Carcinoma, Non-Small-Cell Lung
A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving Durvalumab
Objective in this study is to investigate feasibility of developing machine-learning based model for the identification of future development of diagnosed Grade 2 and higher ILD and of disease progression in patients with…
- Trial name
- iDETECT (NCT04884269)
- Where
- 27 sites in Japan
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Advanced Malignancies
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v.
- Trial name
- NCT02608268
- Testing
- MBG453, PDR001, Decitabine
- Where
- 14 sites in United States, Canada and 7 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
- Conditions
- HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
- Trial name
- NCT04450732
- Testing
- GQ1001
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 96 people
- Sponsor
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
Non-small Cell Lung Cancer Stage IV
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
Primary Objective: to assess the objective response rate (ORR) of Iniparib (SAR240550) administered as a 60-min intravenous infusion twice weekly, when combined to gemcitabine/cisplatin chemotherapy regimen (GCS) as well as with…
- Trial name
- NCT01086254
- Testing
- Iniparib, gemcitabine, cisplatin
- Where
- 14 sites in France, Germany and 3 more
- Volunteers
- 119 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of pralatrexate compared to erlotinib when given to non-small cell lung cancer (NSCLC)…
- Trial name
- NCT00606502
- Testing
- Pralatrexate, Erlotinib, Vitamin B12
- Where
- 47 sites in United States, Argentina and 4 more
- Volunteers
- 201 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.